Protalix BioTherapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• Protalix BioTherapeutics, Inc. showed a decrease of -25.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2008 to 2025), Protalix BioTherapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 65.5%.
• Historical annual values: Fiscal year 2025: $14.68 million | Fiscal year 2024: $19.76 million | Fiscal year 2023: $23.63 million | Fiscal year 2022: $17.11 million | Fiscal year 2021: $38.99 million | Fiscal year 2020: $18.27 million | Fiscal year 2019: $17.79 million | Fiscal year 2018: $37.81 million | Fiscal year 2017: $51.16 million | Fiscal year 2016: $63.28 million | Fiscal year 2015: $76.37 million | Fiscal year 2014: $54.77 million | Fiscal year 2013: $86.40 million | Fiscal year 2012: $52.04 million | Fiscal year 2011: $27.00 million | Fiscal year 2010: $35.90 million | Fiscal year 2009: $81.27 million | Fiscal year 2008: $42.60 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026